NCT04767789View on ClinicalTrials.gov

Clinical Trial to Evaluate the Efficacy and Safety of the Probiotic Strains Limosilactocillus Reuteri DSM 32910 and Lacticaseibacillus Paracasei DSM 32851 on Glucose Homeostatis in Prediabetic Adults

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 12, 2021

Primary Completion Date

November 29, 2022

Study Completion Date

November 29, 2022

Conditions
Prediabetic StateDysglycemia
Interventions
DIETARY_SUPPLEMENT

NZ-GHMH-01

Each randomized subject will consume 1 capsule daily bringing 100 mg (≥ 2 x 109 CFU) of active ingredient during 16 weeks (from V2 to V5 visits).

DIETARY_SUPPLEMENT

Placebo

Each randomized subject will consume 1 capsule with no active ingredient daily during 16 weeks (from V2 to V5 visits).

Trial Locations (8)

44800

Clinical Investigation Unit Biofortis, Saint-Herblain

75012

Clinical Investigation Unit Paris, Paris

720224

"Suceava County Hospital - Spitalul Județean de Urgență Sfântul Ioan cel Nou", Suceava

Unknown

Neomed Brasov, Brasov

"Military Hospital- Spitalul Militar Central Dr Carol Davila", Bucharest

Parhon Institute- Institutul National de Endocrinologie C.I. Parhon, Bucharest

030167

Fundatia Ana Aslan International, Bucharest

G20 0XA

CPS Research, Glasgow

Sponsors

Lead Sponsor

Novozymes A/S
All Listed Sponsors
collaborator

Biofortis, Merieux NutriSciences

INDUSTRY

lead

Novozymes A/S

INDUSTRY

NCT04767789 - Clinical Trial to Evaluate the Efficacy and Safety of the Probiotic Strains Limosilactocillus Reuteri DSM 32910 and Lacticaseibacillus Paracasei DSM 32851 on Glucose Homeostatis in Prediabetic Adults | Biotech Hunter | Biotech Hunter